Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuhan Jinnuosai Biotechnology is a specialized life sciences company focused on the development and production of high-performance cell culture media. Based in the Wuhan National Bio-industry Park (Biolake), the company offers a wide range of products including serum-free, chemically defined, and customized media for various mammalian and insect cell lines such as CHO, HEK293, and Vero. Their portfolio supports the upstream bioprocessing needs of pharmaceutical companies and research institutions working on vaccines, monoclonal antibodies, and recombinant proteins. In addition to product supply, Wuhan Jinnuosai provides technical services such as media screening, process optimization, and cell line adaptation. The company aims to provide cost-effective, high-quality alternatives to imported media products within the Chinese biopharmaceutical market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wuhan Jinnuosai.